Work

A Retrospective Real-World Comparison of Topical Delgocitinib and Localized Cream Psoralen–Ultraviolet A in Chronic Hand Eczema

Year: 2026

Type: article

Abstract: Chronic hand eczema (CHE) remains difficult to treat, particularly in patients unresponsive or intolerant to topical corticosteroids. Although topical delgocitinib, the first topical JAK inhibitor approved for CHE, provides a steroid-free alternative, comparative real-world data versus localized cream psoralen–ultraviolet A (PUVA) are missing. This retrospective real-world study compared the short-term effectiveness and patient-reported outcomes of topical delgocitinib and localized cream PUVA in patients with CHE under routine-care conditions. This retrospective cohort study analyzed anonymized routine-care data of patients with moderate-to-severe CHE treated between 2024 and 2025 at a tertiary center. Patients received topical delgocitinib twice daily or localized cream PUVA with as-needed topical corticosteroids (TCS). Twenty-two patients per group completed 12 weeks of delgocitinib or 20–25 PUVA sessions plus TCS (per-protocol). Disease severity (Physician’s Global Assessment, PGA), quality of life (Dermatology Life Quality Index, DLQI), and symptom numerical rating scales (pruritus, pain, sleep disturbance) were assessed at baseline and treatment end. Both therapies significantly improved all endpoints (p < 0.001). Median DLQI improvement was 10 with delgocitinib versus 7.5 with PUVA (p = 0.15). PGA 0/1 responses were 82% vs 73% (p = 0.72). DLQI improvement ≥ 4 points occurred in 91% vs 77% (p = 0.41). Relapses were more frequent after PUVA. Two delgocitinib non-responders improved with alitretinoin. Most delgocitinib responders continued proactive low-frequency use to maintain remission; one remained clear 3 months after stopping treatment. Delgocitinib and PUVA provided comparable short-term clinical efficacy in CHE, with a numerically greater DLQI reduction for delgocitinib. Proactive delgocitinib maintenance may help sustain disease control. Subtype-adapted treatment strategies could further optimize outcomes. Chronic hand eczema (CHE) is a condition that has a major impact on a patient’s daily life and brings therapeutic challenge. It affects daily activities, work, and quality of life. Standard treatments such as steroid creams or photochemotherapy (psoralen–ultraviolet A; PUVA) often require frequent hospital visits and may not be suitable for long-term use. Delgocitinib cream is a new non-steroidal treatment that reduces inflammation in the skin. This study was conducted in Germany at the Department of Dermatology of LMU Munich. We reviewed medical records of 51 adults who received either delgocitinib or localized PUVA as part of routine care. The aim was to understand how well these treatments work in real-world clinical practice. Both treatments improved symptoms and quality of life. Delgocitinib and PUVA showed similar short-term effectiveness. Because delgocitinib is a topical therapy that can be applied at home, some patients found it easier to use in everyday life, while PUVA required regular hospital visits. In several PUVA-treated patients, symptoms returned after stopping treatment, highlighting the need for ongoing management in CHE. Our findings suggest that both treatments are useful options in clinical practice, with different advantages depending on patient needs and circumstances.

Source: Dermatology and Therapy

DOI: 10.1007/s13555-026-01705-1